Ikena Oncology Inc. has nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as the company's first development candidate in the RAS pathway. IK-595 traps MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors.